Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

DPP-4 Inhibitors May Protect Against Hypoglycemia

Aims/hypothesis Glucose-lowering therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with a low risk of hypoglycaemia. We hypothesise that DPP-4 inhibition prevents hypoglycaemia via increased glucagon counterregulation through the incretin ho

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Aims/hypothesis Glucose-lowering therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with a low risk of hypoglycaemia. We hypothesise that DPP-4 inhibition prevents hypoglycaemia via increased glucagon counterregulation through the incretin hormone glucose-dependent insulinotropic polypeptide (GIP). Methods Using a hyperinsulinaemic–hypoglycaemic clamp that targeted 2.5 mmol/l we examined the effects of the DPP-4 inhibitor vildagliptin and GIP infusion on steady state glucose infusion rate (GIR) and glucagon counterregulation in mice. Following up on this, we performed a hyperinsulinaemic–hypoglycaemic clamp in mice carrying a genetic deletion of the GIP receptor (GIPR − / − mice) or the glucagon receptor (GCGR − / − mice). READ FULL ARTICLE From Springer

P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

Ketosis-Prone Type 2 Diabetes Medication: Antidiabetics, Alpha-Glucosidase Inhibitors, Antidiabetics, Amylinomimetics, Antidiabetics, Biguanides, Antidiabetics, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors, Antidiabetics, Glucagon-like Peptide-1 Agonists, Antidiabetics, Glucose-dependent Insulinotropic Polypeptides, Antidiabetics, Insulins, Antidiabetics, Meglitinide Derivatives, Antidiabetics, SGLT2 Inhibitors, Antidiabetics, Sulfonylureas, Antidiabetics, Thiazolidinediones, Antiparkinson Agents, Dopamine Agonists, Bile Acid Sequestrants, Hypoglycemia Antidotes

Gaba R, Mehta P, Balasubramanyam A. Evaluation and management of ketosis-prone diabetes. Expert Rev Endocrinol Metab . 2019 Jan. 14 (1):43-8. [QxMD MEDLINE Link] . Boike S, Mir M, Rauf I, et al. Ketosis-prone …

Read guide →
02
Peptide Therapy Guide Editorial Team

Type 2 Diabetes Mellitus Medication: Antidiabetics, Biguanides, Antidiabetics, Glucagon-like Peptide-1 Agonists, Antidiabetics, SGLT2 Inhibitors, Antidiabetics, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors, Antidiabetics, Sulfonylureas, Antidiabetics, Meglitinide Derivatives, Antidiabetics, Alpha-Glucosidase Inhibitors, Antidiabetics, Thiazolidinediones, Aldosterone Antagonists, Selective, Antidiabetics, Amylinomimetics, Bile Acid Sequestrants, Antiparkinson Agents, Dopamine Agonists, Antidiabetics, Rapid-Acting Insulins, Antidiabetics, Short-Acting Insulins, Antidiabetics, Intermediate-Acting Insulins, Antidiabetics, Long-Acting Insulins

Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care . 2003 Jan. 26 Suppl 1:S5-20. [QxMD MEDLINE Link] . Parker ED, Lin J, Mahoney T, et al. Economic Costs of …

Read guide →